Recent initiatives in Scotland to improve the quality and efficiency of prescribing : findings and implications by Kurdi, Amanj et al.
Kurdi, Amanj and Godman, Brian and MacBride-Stewart, Sean and 
Hurding, Simon and McCabe, Holly and Morton, Alexander David (2018) 
Recent initiatives in Scotland to improve the quality and efficiency of 
prescribing : findings and implications. In: 34th International Conference 
on Pharmacoepidemiology and Therapeutic Risk Management, 2018-08-
22 - 2018-08-26, The Prague Congress Centre. (In Press) , 
This version is available at https://strathprints.strath.ac.uk/63995/
Strathprints is  designed  to  allow  users  to  access  the  research  output  of  the  University  of 
Strathclyde. Unless otherwise explicitly stated on the manuscript, Copyright © and Moral Rights 
for the papers on this site are retained by the individual authors and/or other copyright owners. 
Please check the manuscript for details of any other licences that may have been applied. You 
may  not  engage  in  further  distribution  of  the  material  for  any  profitmaking  activities  or  any 
commercial gain. You may freely distribute both the url (https://strathprints.strath.ac.uk/) and the 
content of this paper for research or private study, educational, or not-for-profit purposes without 
prior permission or charge. 
Any correspondence concerning this service should be sent to the Strathprints administrator: 
strathprints@strath.ac.uk
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research 
outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the 
management and persistent access to Strathclyde's intellectual output.
 
RECENT INITIATIVES IN SCOTLAND TO IMPROVE THE QUALITY AND EFFICIENCY OF 
PRESCRIBING; FINDINGS AND IMPLICATIONS  
 
Amanj Kurdi1, Brian Godman1,2, Sean MacBride-Stewart3, Simon Hurding4, Holly McCabe5, Alec 
Morton5 
 
1Strathclyde Institute of Pharmacy and Biomedicial Sciences, University of Strathclyde, Glasgow, 
United Kingdom  
2Division of Clinical Pharmacology, Karolinska, Karolinska Institutet, Stockholm, Sweden 
3NHS GGC, Scotland 
4NHS Scotland 
5Management Sciences, University of Strathclyde, Glasgow, United Kingdom 
 
Key words: Drug utilisation, generics, Scotland 
 
Background: Changing demographics with an increase in chronic disease prevalence coupled with 
more aggressive management targets, and the continued launch of new premium priced products, 
has put considerable strain on healthcare systems to continue providing universal, high quality 
healthcare. High appropriate use of generics in a class where care is not compromised by prescribing 
generics versus patented products, combined with quality measures, can help with providing quality 
healthcare. Objective: Assess the utilisation and costs of lipid lowering therapies (C10), Proton-Pump 
Inhibitors (PPIs) (A02BC), and Selective Serotonin Reuptake Inhibitors (SSRIs) (N06AB) in 
ambulatory care in Scotland between 2001 and 2015 alongside reforms to provide future guidance. 
Methods: Utilisation measured in the number of items dispensed to assess prescriptions and 
reimbursed expenditure captured in GB pounds from NHS Scotland national database. National and 
regional initiatives to improve the quality and efficiency of prescribing were captured using standard 
methodologies (4Es - education, engineering, economics and enforcement). No time series analyses 
analysis was conducted as multiple interventions over time. Results: Lipid lowering therapies (statins 
predominantly): multiple initiatives including identifying patients with CHD, encouraging preferential 
prescribing of generics, reducing ezetimibe prescribing as little evidence of benefit, and encouraging 
the prescribing of higher dose statins in line with recommendations, resulted in statin expenditure 
falling by 56% in 2015 vs. 2001 despite a 4.03 fold increase in utilisation. High dose statins now 
account for 71.3% of total prescriptions, up from 17.3% in 2001. PPIs: similar multiple initiatives 
resulted in a 68% reduction in expenditure despite a 2.91 fold increase in utilisation. High dose 
prescribing reduced to 20.3% of all PPIs in 2015, down from 25.8% in 2009, following concerns. 
SSRIs: similar initiatives and encouraging citalopram vs. escitalopram resulted in expenditure falling 
by 60.1% despite a 2.12 fold increase in utilisation. Concerns with citalopram in 2012 saw its 
prescribing fall in recent years whilst the prescribing of sertraline has grown. The prescribing of 
paroxetine continually fell from 2002 onwards as a result of concerns. Conclusion: Multiple strategies 
have been successful with improving the quality and efficiency of prescribing in Scotland. These will 
continue. 
 
 
 
